非放射線性脊椎軸関節炎治療薬の世界市場レポート2025年

非放射線学的軸索脊椎関節炎治療薬の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.7%で15億5,000万米ドルに成長します。予測期間中に予想される成長は、疾患に対する認知度の向上と早期発見、バイオシミラーの普及、生物学的製剤の継続的な改良と今後の治療イノベーション、研究開発への注力の高まり、標的化・個別化治療戦略の普及、ヘルスケアインフラの進歩に関連すると考えられます。この期間に予想される顕著な動向には、個別化治療アプローチの開発、診断のためのデジタルツールの使用、treat-to-target戦略への嗜好の高まり、価値に基づく価格設定の枠組みの導入、集学的管理モデルの広範な採用などがあります。

臨床試験の増加は、非放射線性脊椎軸関節炎治療薬市場の成長を促進すると予想されます。臨床試験はヒトを対象に実施される調査研究であり、治療や介入の安全性、有効性、副作用を評価するために不可欠です。臨床試験の増加は、安全性と有効性を確保するために厳格な試験を必要とする個別化された革新的な治療に対する需要の高まりによるところが大きいです。これらの臨床試験は、早期疾患における治療の有効性と安全性をエビデンスに基づいて検証するものであり、規制当局の承認や非放射線性軸椎関節炎治療薬の臨床採用を導く上で極めて重要です。例えば、英国を拠点とする業界団体である英国製薬工業協会は2023年11月、英国における業界臨床試験の年間募集人数が15％増加し、参加者数が2021-22年の3万6,722人から2022-23年には4万2,088人に増加すると報告しました。この動向は、臨床試験数の増加が市場拡大に大きく寄与していることを示しています。

非放射線性軸索脊椎関節炎（nr-axSpA）治療薬市場で事業を展開する企業は、市場でのプレゼンスを拡大し、新規治療薬の市場投入までの時間を短縮し、競合優位性を獲得するために、規制当局の承認取得にますます注力するようになっています。規制当局の承認には政府機関からの正式な認可が含まれ、安全性、有効性、基準への準拠が確認されれば、医薬品や治療法の合法的な販売や処方が可能になります。例えば、2022年10月、米国のバイオ医薬品会社であるアッヴィ・インクは、客観的な炎症徴候があり、TNF阻害剤で十分な効果が得られない活動性の非放射線性軸性脊椎関節炎の成人の治療薬として、リンボック（ウパダシチニブ）のFDA承認を取得しました。今回の承認により、リンボックは米国で6番目の適応となり、非神経性腋窩脊椎炎に対して承認された最初で唯一の経口JAK阻害剤となります。今回の決定は、SELECT-AXIS 2臨床試験の結果に基づいており、Rinvoqを投与された患者の半数近くが、プラセボを投与された患者と比較して、14週時点で疾患活動性が有意に改善したことを示しています。今回の承認は、この課題に直面している患者さんにとって、1日1回経口投与の新たな治療選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の非放射線性脊椎軸関節炎治療薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の非放射線性脊椎軸関節炎治療薬市場：成長率分析
• 世界の非放射線性脊椎軸関節炎治療薬市場の実績：規模と成長, 2019-2024
• 世界の非放射線性脊椎軸関節炎治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の非放射線性脊椎軸関節炎治療薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の非放射線性脊椎軸関節炎治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬
• 生物学的製剤
• 小分子療法
• コルチコステロイド
• 世界の非放射線性脊椎軸関節炎治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 世界の非放射線性脊椎軸関節炎治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• 在宅ケア設定
• 世界の非放射線性脊椎軸関節炎治療薬市場非ステロイド性抗炎症薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• COX-2阻害剤
• 非選択的NSAIDs
• 世界の非放射線性脊椎軸関節炎治療薬市場、生物製剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍壊死因子（TNF）阻害剤
• インターロイキン-17（IL-17）阻害剤
• 世界の非放射線性脊椎軸関節炎治療薬市場低分子治療薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヤヌスキナーゼ（JAK）阻害剤
• ホスホジエステラーゼ4（PDE4）阻害剤
• 世界の非放射線性脊椎軸関節炎治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口コルチコステロイド
• 関節内コルチコステロイド注射

第7章 地域別・国別分析

• 世界の非放射線性脊椎軸関節炎治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の非放射線性脊椎軸関節炎治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非放射線性脊椎軸関節炎治療薬市場：競合情勢
• 非放射線性脊椎軸関節炎治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Allergan plc Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Novo Nordisk A/S
• Biogen Inc.
• Daiichi Sankyo Company Limited
• UCB S.A.
• Mochida Pharmaceutical Co. Ltd.
• Mereo BioPharma Group plc
• Suzhou Zelgen Biopharmaceuticals Co. Ltd.
• Qyuns Therapeutics Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非放射線性脊椎軸関節炎治療薬市場2029：新たな機会を提供する国
• 非放射線性脊椎軸関節炎治療薬市場2029：新たな機会を提供するセグメント
• 非放射線性脊椎軸関節炎治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-radiographic axial spondyloarthritis therapeutics refer to treatments designed to manage symptoms and slow disease progression in individuals who do not exhibit visible joint damage on X-rays. These therapies primarily include non-steroidal anti-inflammatory drugs (NSAIDs), biologic treatments such as TNF and IL-17 inhibitors, and JAK inhibitors. The primary objectives are to alleviate inflammation, enhance physical function, and prevent the emergence of radiographic changes in the spine and joints.

The key categories of non-radiographic axial spondyloarthritis therapies include non-steroidal anti-inflammatory drugs, biologics, small molecule treatments, and corticosteroids. NSAIDs help reduce inflammation, pain, and fever by blocking enzymes involved in the production of prostaglandins. These drugs can be administered through oral, injectable, and topical methods and are utilized across various settings, including hospitals, ambulatory surgical centers, and homecare environments.

The non-radiographic axial spondyloarthritis therapeutic market research report is one of a series of new reports from The Business Research Company that provides non-radiographic axial spondyloarthritis therapeutic market statistics, including non-radiographic axial spondyloarthritis therapeutic industry global market size, regional shares, competitors with a non-radiographic axial spondyloarthritis therapeutic market share, detailed non-radiographic axial spondyloarthritis therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the non-radiographic axial spondyloarthritis therapeutic industry. This non-radiographic axial spondyloarthritis therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-radiographic axial spondyloarthritis therapeutics market size has grown rapidly in recent years. It will grow from $0.93 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period is due to various factors such as an increase in the prevalence of axial spondyloarthritis, rising disease awareness, a growing patient population, expanding adoption of biologic therapies, and heightened research and development efforts.

The non-radiographic axial spondyloarthritis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.55 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The anticipated growth during the forecast period can be linked to the rising awareness and early detection of the condition, proliferation of biosimilars, continuous improvements in biologic drugs and upcoming treatment innovations, increasing focus on R&D, a higher uptake of targeted and personalized treatment strategies, and advancements in healthcare infrastructure. Prominent trends expected during this period include development of personalized therapeutic approaches, use of digital tools for diagnosis, a growing preference for treat-to-target strategies, implementation of value-based pricing frameworks, and broader adoption of multidisciplinary management models.

The increasing number of clinical trials is expected to propel the growth of the non-radiographic axial spondyloarthritis therapeutic market. Clinical trials, which are research studies conducted on humans, are essential for evaluating the safety, effectiveness, and side effects of medical treatments or interventions. The rise in clinical trials is largely driven by the growing demand for personalized and innovative treatments that require rigorous testing to ensure safety and efficacy. These trials provide evidence-based validation of treatment effectiveness and safety in early-stage disease, which is critical for guiding regulatory approvals and clinical adoption of non-radiographic axial spondyloarthritis therapeutics. For example, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported a 15% increase in annual recruitment to industry clinical trials in the UK, with participant numbers rising from 36,722 in 2021-22 to 42,088 in 2022-23. This trend indicates that the growing number of clinical trials is significantly contributing to market expansion.

Companies operating in the non-radiographic axial spondyloarthritis (nr-axSpA) therapeutic market are increasingly focusing on securing regulatory approvals to broaden their market presence, reduce time-to-market for new therapies, and gain a competitive edge. Regulatory approvals involve official authorization from government agencies, allowing drugs or therapies to be legally marketed and prescribed once their safety, efficacy, and compliance with standards have been verified. For instance, in October 2022, AbbVie Inc., a US-based biopharmaceutical company, received FDA approval for Rinvoq (upadacitinib) to treat adults with active non-radiographic axial spondyloarthritis who have objective signs of inflammation and have not responded adequately to TNF inhibitors. This approval marks the sixth U.S. indication for Rinvoq and makes it the first and only oral JAK inhibitor approved for nr-axSpA. The decision was based on results from the SELECT-AXIS 2 clinical trial, which showed that nearly half of the patients treated with Rinvoq experienced significant improvements in disease activity at 14 weeks compared to those receiving a placebo. This approval offers a new once-daily oral treatment option for patients facing this challenging condition.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired DICE Therapeutics for an undisclosed sum. The acquisition aims to bolster Eli Lilly's immunology portfolio by integrating DICE's promising oral IL-17 inhibitors for autoimmune diseases. This move enhances Eli Lilly's capacity to address chronic inflammatory conditions with innovative and patient-friendly oral therapies. DICE Therapeutics, a US-based biopharmaceutical company, is known for its oral IL-17 antagonists, including DC-806 and DC-853, developed for treating non-radiographic axial spondyloarthritis and other autoimmune diseases.

Major players in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc., Johnson & Johnson, Allergan plc, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Mochida Pharmaceutical Co. Ltd., Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co. Ltd., and Qyuns Therapeutics Co. Ltd.

North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2024. The regions covered in non-radiographic axial spondyloarthritis therapeutic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-radiographic axial spondyloarthritis therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-radiographic axial spondyloarthritis therapeutic market consists of sales of TNF inhibitors, JAK inhibitors, non-steroidal anti-inflammatory drugs, and IL-23 inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Radiographic Axial Spondyloarthritis Therapeutic Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-radiographic axial spondyloarthritis therapeutic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-radiographic axial spondyloarthritis therapeutic ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-radiographic axial spondyloarthritis therapeutic market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Non-Steroidal Anti-Inflammatory Drugs; Biologics; Small Molecule Therapies; Corticosteroids
• 2) By Application: Oral; Injectable; Topical
• 3) By End User: Hospitals; Ambulatory Surgical Centers; Homecare Settings
• Subsegments:
• 1) By Non-Steroidal Anti-Inflammatory Drugs: COX-2 Inhibitors; Non-Selective NSAIDs
• 2) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-17 (IL-17) Inhibitors
• 3) By Small Molecule Therapies: Janus Kinase (JAK) Inhibitors; Phosphodiesterase-4 (PDE4) Inhibitors
• 4) By Corticosteroids: Oral Corticosteroids; Intra-Articular Corticosteroid Injections
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Allergan plc; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Characteristics

3. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Trends And Strategies

4. Non-Radiographic Axial Spondyloarthritis Therapeutic Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Radiographic Axial Spondyloarthritis Therapeutic PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market Growth Rate Analysis
• 5.4. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Total Addressable Market (TAM)

6. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Segmentation

• 6.1. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs
• Biologics
• Small Molecule Therapies
• Corticosteroids
• 6.2. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.3. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Homecare Settings
• 6.4. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Sub-Segmentation Of Non-Steroidal Anti-Inflammatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• COX-2 Inhibitors
• Non-Selective NSAIDs
• 6.5. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin-17 (IL-17) Inhibitors
• 6.6. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Sub-Segmentation Of Small Molecule Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Janus Kinase (JAK) Inhibitors
• Phosphodiesterase-4 (PDE4) Inhibitors
• 6.7. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Corticosteroids
• Intra-Articular Corticosteroid Injections

7. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Regional And Country Analysis

• 7.1. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 8.1. Asia-Pacific Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 9.1. China Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 9.2. China Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 10.1. India Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 11.1. Japan Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 11.2. Japan Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 12.1. Australia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 13.1. Indonesia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 14.1. South Korea Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 14.2. South Korea Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 15.1. Western Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 15.2. Western Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 16.1. UK Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 17.1. Germany Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 18.1. France Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 19.1. Italy Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 20.1. Spain Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 21.1. Eastern Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 21.2. Eastern Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 22.1. Russia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 23.1. North America Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 23.2. North America Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 24.1. USA Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 24.2. USA Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 25.1. Canada Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 25.2. Canada Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 26.1. South America Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 26.2. South America Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 27.1. Brazil Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 28.1. Middle East Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 28.2. Middle East Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Radiographic Axial Spondyloarthritis Therapeutic Market

• 29.1. Africa Non-Radiographic Axial Spondyloarthritis Therapeutic Market Overview
• 29.2. Africa Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Radiographic Axial Spondyloarthritis Therapeutic Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Competitive Landscape And Company Profiles

• 30.1. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Competitive Landscape
• 30.2. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Allergan plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Non-Radiographic Axial Spondyloarthritis Therapeutic Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc.
• 31.7. Amgen Inc.
• 31.8. Novo Nordisk A/S
• 31.9. Biogen Inc.
• 31.10. Daiichi Sankyo Company Limited
• 31.11. UCB S.A.
• 31.12. Mochida Pharmaceutical Co. Ltd.
• 31.13. Mereo BioPharma Group plc
• 31.14. Suzhou Zelgen Biopharmaceuticals Co. Ltd.
• 31.15. Qyuns Therapeutics Co. Ltd.

32. Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market

34. Recent Developments In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market

35. Non-Radiographic Axial Spondyloarthritis Therapeutic Market High Potential Countries, Segments and Strategies

• 35.1 Non-Radiographic Axial Spondyloarthritis Therapeutic Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Radiographic Axial Spondyloarthritis Therapeutic Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Radiographic Axial Spondyloarthritis Therapeutic Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer